Commitments and Contingencies
|12 Months Ended|
Jun. 30, 2020
|Commitments And Contingencies Disclosure [Abstract]|
|Commitments and contingencies||
The Company has the following obligations over the next five fiscal years ending June 30, 2025:
The Company has entered into contracts for drug manufacturing, clinical study management and safety related to its Phase II clinical trials, and a one-year loan (note 11) for a total of $1,419,520. Pursuant to the commitment for clinical trial management, the Company has paid a total of $41,938 in deposits related to study initiation and certain study costs. These deposits are available to be applied against invoices received from the contract research organization but have not been netted against the Company’s commitments for the fiscal year ended June 30, 2020.
The Company currently rents its shared head office on a one-year renewable lease at $189 per month. The Company also rents its administrative offices on a month-to-month basis at a rate of $3,187 (CA$4,357) per month. During the year ended June 30, 2020, the Company recorded a total of $40,130 as rent expense (2019 - $52,926).
The entire disclosure for commitments and contingencies.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef